Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
Biomedtracker
15 Aug 2018
What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Biomedtracker
15 Aug 2018
Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter.
Meddevicetracker
14 Aug 2018
In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology, and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.
Scrip
By Mandy Jackson 14 Aug 2018
Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.
Scrip
By Jules Quartly 14 Aug 2018
The market debuts of BeiGene and Ascletis on the new Hong Kong Stock Exchange’s Biotech section could further encourage other Chinese biotech companies as they seek to draw in a wider pool of investors and focus on the promising domestic sector.
Pink Sheet
By Bridget Silverman 14 Aug 2018
Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.
Topic FDA
In Vivo
By William Looney 13 Aug 2018
The 16 million survivors of cancer in the US today form a restless constituency with its own disparate set of interests – and by sheer weight of numbers is beginning to direct changes to medical practice that pose both risks and opportunity for biopharma.
Topic Cancer
Scrip
By Brian Yang 09 Aug 2018
Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.
Topic Policy and regulation
Pink Sheet
By Ian Schofield 09 Aug 2018
A ruling by the Court of Justice of the EU has attempted to clarify the situation regarding the conditions for a supplementary protection certificate, but while it may help to settle the UK case regarding Gilead’s combination HIV drug Truvada, one practitioner says the case raises more questions than it answers.
Topic Policy and regulation
Medtech Insight
By Sue Darcey 09 Aug 2018
An analysis of Supreme Court nominee Brett Kavanaugh’s prior rulings opposing the Affordable Care Act, and how his weight on ACA cases coming before the high court may remove some marketplace insurance for medtech products for preexisting illnesses and mental health that are currently covered. The third of a multi-part Medtech Insight feature series on what a more conservative Supreme Court could mean for future court decisions that impact the medical device industry.
Topic Medtech
Scrip
By Cathy Kelly 09 Aug 2018
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
Scrip
By Jung Won Shin 09 Aug 2018
The Korean biotech’s CEO and several other executives’ alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.
Citeline, Citeline Analytics
By Laura Runkel 07 Aug 2018
For a deeper look into the data behind last year’s completed clinical trials and the trends driving them, Listen to the Completed Clinical Trials 2017: Status Quo or No?
Topic Clinical trials
In Vivo
By Amama Sadiq, Iliyana P. Atanasova, Katherine J. Franklin 03 Aug 2018
Drug development for nonalcoholic steatohepatitis (NASH), a form of liver disease, is a game of incomplete information: pipeline evolution is occurring in parallel with continued efforts to better understand and manage the disease. To date, no therapy for patients with NASH has been approved and consequences of the condition can be severe, including cirrhosis and hepatocellular carcinoma.
Topic Clinical trials
Scrip
By Jo Shorthouse 03 Aug 2018
Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.
Topic Clinical trials
Pink Sheet
15 Aug 2018
Pink Sheet
15 Aug 2018
Medtech Insight
15 Aug 2018
Scrip
15 Aug 2018
In Vivo
15 Aug 2018
Medtech Insight
15 Aug 2018
Pink Sheet
15 Aug 2018
Scrip
14 Aug 2018
Pink Sheet
14 Aug 2018
Pink Sheet
14 Aug 2018
Medtech Insight
14 Aug 2018
Pink Sheet
14 Aug 2018
Pink Sheet
14 Aug 2018
Pink Sheet
14 Aug 2018
Pink Sheet
14 Aug 2018
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
26 Aug 2018 , 09:30 CST
Switzerland
Industry conference
06 Sep 2018
Industry conference
23 Sep 2018
USA
Awards
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Keep up to date